Radiation therapy for BCG-resistant bladder CIS
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests radiotherapy (high-energy X-rays) for a specific type of early-stage bladder cancer (CIS) that hasn't gone away after BCG treatment. It's for people who can't or choose not to have bladder removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bladder cancer called carcinoma in situ (CIS) that is high-risk and did not respond to BCG therapy.
- Your cancer should not have spread into the bladder muscle or to other organs.
- You must be 18 years or older and in reasonably good health (able to do daily activities).
- You should be willing to use effective birth control during and for 4 weeks after treatment.
- You must not have had radiation to the pelvis in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
This study tests if BCG therapy can prevent bladder cancer from coming back after surgery. It's for people with early-stage bladder cancer that hasn't spread into the muscle layer.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial tests whether radiation therapy can help people whose bladder cancer (specifically carcinoma in situ) did not get better with BCG treatment and who are not having their bladder removed. It aims to offer a less invasive option for controlling the cancer.
This trial compares radiotherapy with a radiosensitizer to BCG therapy for people with high-risk non-muscle invasive bladder cancer. The goal is to see which treatment better controls the cancer and helps patients avoid bladder removal.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.